Janssen and Legend Biotech have begun a rolling submission of a biologics license application for ciltacabtagene autoleucel, or cilta-cel, their chimeric antigen receptor T-cell therapy candidate. The partners are seeking approval as a treatment for adults with relapsed or refractory multiple myeloma.
Rolling submission initiated for CAR T-cell therapy
Sign up for AANP SmartBrief
News for nurse practitioners
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.